Sil­ver­back falls on hard times, ax­ing lead I/O can­di­dates and lay­ing off more than a fourth of staff

Sil­ver­back Ther­a­peu­tics be­came the lat­est biotech to un­der­take a “strate­gic re­align­ment” Thurs­day, re­veal­ing it would drop its two lead can­cer pro­grams — send­ing it back to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER